伊德本通过通过向阿克特信号来调节自,减轻糖尿病视网膜病变
1Department of Endocrinology, Shandong University QILU Hospital, China.
Current medicinal chemistry
|November 4, 2024
概括
通过PI3K信号通路调节自和亡,idebenone (IDE) 治疗逆转了糖尿病视网膜病变 (DR) 中的血管功能障碍和视网膜损伤.
科学领域:
- 眼科医生 眼科 眼科
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病视网膜病变 (DR) 是糖尿病的一个微血管并发症.
- 作为一种辅酶Q10模拟物,idebenone (IDE) 具有抗氧化特性,用于神经退行性疾病.
研究的目的:
- 调查Idebenone (IDE) 在治疗糖尿病视网膜病变 (DR) 的治疗潜力.
- 阐明DR中IDE作用的基础分子机制.
主要方法:
- 糖尿病视网膜病变的体内大鼠模型是使用链条毒素 (STZ) 诱导的.
- 使用超声波评估血管功能,并通过HE染色检查视网膜结构.
- 自和亡的生物标志物使用西式涂抹量化.
- 在体外研究中使用高葡萄糖刺激的RF / 6A视网膜内皮细胞治疗IDE,评估增殖和亡.
主要成果:
- IDE治疗逆转了STZ诱导的血管功能障碍 (改善PSV,MV,EDV;减少PI,RI) 和视网膜结构损伤.
- 在体内和体内,IDE的使用抑制了DR诱导的自和亡.
- IDE抑制PI3K信号通路的激活,这与IDE的保护作用有关.
结论:
- 伊德本 (IDE) 在缓解糖尿病视网膜病变方面表现出治疗疗效.
- IDE通过调节PI3K信号通路来调节视网膜细胞自和亡.
相关概念视频
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Insulin: The Receptor and Signaling Pathways
1.1K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.1K
Dipeptidyl Peptidase 4 Inhibitors
172
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
172
Electron Transport Chain: Complex I and II
11.9K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
11.9K
Oral Hypoglycemic Agents: Biguanides and Glitazones
175
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
175


